摘要
目的:分析晚期卵巢癌患者采用新辅助化疗的应用效果。方法:选取本院2017年6月-2019年6月诊治的56例晚期卵巢癌患者开展本次研究,选取随机数字表法将所有患者均分为参照组和研究组,各28例。参照组术后给予新辅助化疗治疗,研究组术前术后给予新辅助化疗,比较两组临床疗效。结果:与参照组术中出血量、手术时间、腹水量和术前CA125指标相比,研究组均明显低(P<0.05);与参照组治疗有效率相比,研究组明显高(P<0.05);与参照组并发症发生率相比,研究组明显低(P<0.05)。结论:给予晚期卵巢癌患者术前术后新辅助化疗能够显著改善患者的临床疗效,能够有效提升患者的安全性,具有推广价值。
Objective:To analyze the effect of neoadjuvant chemotherapy in patients with advanced ovarian cancer.Method:A total of 56 patients with advanced ovarian cancer in our hospital from June 2017 to June 2019 were selected for this study.All patients were randomly divided into the reference group and the study group with 28 cases in each group.The reference group was given neoadjuvant chemotherapy after operation,and the study group was given neoadjuvant chemotherapy before and after operation.The clinical effect in two groups was compared.Result:Compared with the reference group,the bleeding volume,operation time,ascites volume and CA125 index in the study group were significantly lower(P<0.05).Compared with the reference group,the treatment effective rate of the study group was significantly higher(P<0.05).Compared with the reference group,the incidence of complications in the study group was significantly lower(P<0.05).Conclusion:Neoadjuvant chemotherapy for patients with advanced ovarian cancer before and after surgery can significantly improve the clinical efficacy of patients,can effectively improve the safety of patients,has the promotion value.
作者
林飞峰
阮舆鑫
宋保志
LIN Feifeng;RUAN Yuxin;SONG Baozhi(Fujian Provincial Hospital,Fuzhou 350001,China;不详)
出处
《中外医学研究》
2020年第29期62-64,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
福建省自然科学基金资助项目(2017J01254)。
关键词
晚期卵巢癌
新辅助化疗
治疗效果
Advanced ovarian cancer
Neoadjuvant chemotherapy
Therapeutic effect
